A detailed history of Campbell Newman Asset Management Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Campbell Newman Asset Management Inc holds 1,773 shares of VRTX stock, worth $841,412. This represents 0.06% of its overall portfolio holdings.

Number of Shares
1,773
Previous 1,782 0.51%
Holding current value
$841,412
Previous $725,000 2.21%
% of portfolio
0.06%
Previous 0.06%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 16, 2024

SELL
$407.69 - $446.08 $3,669 - $4,014
-9 Reduced 0.51%
1,773 $741,000
Q4 2023

Jan 24, 2024

SELL
$343.0 - $410.68 $8,575 - $10,267
-25 Reduced 1.38%
1,782 $725,000
Q3 2023

Oct 19, 2023

SELL
$338.18 - $362.46 $1,352 - $1,449
-4 Reduced 0.22%
1,807 $628,000
Q2 2023

Jul 24, 2023

SELL
$314.42 - $351.91 $4,716 - $5,278
-15 Reduced 0.82%
1,811 $637,000
Q1 2023

Apr 28, 2023

BUY
$283.23 - $323.1 $517,177 - $589,980
1,826 New
1,826 $575,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Campbell Newman Asset Management Inc Portfolio

Follow Campbell Newman Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Campbell Newman Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Campbell Newman Asset Management Inc with notifications on news.